Osteoporosis is a commonly observed bone disease that weakens bone and further enhance the risk of bone breaking. This condition makes bone fragile thus increasing the susceptibility of fracture. According to International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds.
A peptic ulcer is forms of painful sores that develops on the mucosal lining of the stomach, small intestine or lower esophagus. Increase in prevalence of H. Pylori infection, improved diagnostic techniques, easy availability of treatment medication, preferable use of peptic ulcer medication over surgery, increase in rate of smocking and over use of NSAIDs are driving the growth of peptic ulcer drugs market globally.
Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is a neurological disease that causes death of nerve cells that control voluntary muscles. Factors such, increase in incidence of ALS, strong pipeline molecule, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.
This report on global multiple drug resistance bacterial infection treatment market studies various vectors and drug class. Rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market growth. The limiting factors related to this market are the complex regulatory approvals for the antibiotics which varies according to countries.
This report on global tuberculosis treatment market studies various drug class. According to World Health Organization (WHO) approximately 49 million lives were saved from 2000-2015 through effective diagnosis and treatment, its end TB strategy aims to eradicate the global TB epidemic with 95% reduction in TB deaths, and to cut new cases by 90% from 2015 to 2035 and to ensure that patients are not burdened with huge expenses incurred due to TB.
Cartilage is smooth elastic tissue that protects the ends of bones at the joints by preventing friction between the bones. Factors such as growing incidence of sports injuries, increase in prevalence of bone disorders, rising geriatric and obese population are prime factors that driving the growth of cartilage repair regeneration market globally.
Chemotherapy induced neutropenia is a very common side effect of cancer chemotherapy, it is treated on the basis of etiology, severity, and duration of the neutropenia. Growing prevalence of different forms of cancer and increasing research and development activities for novel therapeutics are primarily driving the growth of chemotherapy induced neutropenia market globally.
Phototherapy refers to the use of light to treat medical conditions. Phototherapy incorporates the use of ultraviolet rays, particularly UVA and UVB wavelength. Broadband UVB, narrowband UVB and PUVA (Psoralen + UVA) are the major UV forms used in phototherapy. UVB is used to treat skin diseases such as atopic eczema, psoriasis, vitiligo, generalised itching and other skin conditions.
Post-Traumatic Stress Disorder Therapeutics Market is expected to grow at a compound annual growth rate of 5% for the forecast period of 2021 to 2029. The increase has been primarily due to increase in violence incidents, accidents and occupational hazards. This report covers all the quantitative aspects of the Post- Traumatic Stress Disorder Therapeutics marketand also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.
The global allergy diagnosis market is developing significantly with an expected CAGR of above 7.5% from 2019 - 2029. Advances in technological processes are the key growth factor. Skin prick test (SPT) has been highly recommended by European doctors as it is more accurate & least expensive., Introduction of various kinds of kits and instruments have simplified the process of skin prick test (SPT) in the recent years., This led to increase in the revenues and created significant market opportunities.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.